ong-term treatment of Scalp Psoriasis with Calciptriol plus Betamethasone dipropionate gel.A phase III safety study of a new gel containing calcipotriol 50mcg/g plus betamethasone 0.5 mg/g (as dipropionate) used once daily, as needed, in scalp psoriasis.

EO Pharma A/S0 个研究点目标入组 800 人开始时间: 2004年12月21日最近更新: 2016年10月3日

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方
入组人数: 800

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•1. Scalp psoriasis amenable to topical treatment with a maximum of 100 g of study medication per week
•2. Clinical signs of psoriasis vulgaris on trunk and/or limbs, or earlier diagnosed with psoriasis vulgaris on trunk and/or limbs
•3. Extent of scalp psoriasis involving more than 10% of the total scalp area
•4. Disease severity on the scalp graded as Moderate, Severe or Very Severe according to the Investigator’s Global Assessment of disease severity
•5. Patients aged 18 years or above
•6. Patients may be of either sex
•7. Patients may be of any ethic origin
•8. Attending a hospital out-patient clinic, the private practice of a dermatologist or the practice of a general practitioner experienced in the handling of psoriasis vulgaris
•9. Following verbal and written information about the trial, the patient must provide signed and dated informed consent before any study related activity is carried out, including washout
•10. Patients must fulfil all relevant national requirements/laws for participation in this study
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

排除标准

•1. PUVA or Grentz ray therapy anywhere on the patient within 28 days prior to randomisation
•2. UVB therapy anywhere on the patient within 14 days prior to randomisation
•3. Systemic use of biological treatments, whether marketed or not, directed against or with a potential effect on, scalp psoriasis (e.g., alefacept, efalizumab, etanercept, infliximab) within 6 months prior to randomisation.
•4. Systemic treatments with a potential effect on scalp psoriasis vulgaris (e.g. corticosteroids, retinoids, immunosuppressants) within 28 days prior to randomisation.
•5. Any topical treatment for scalp psoriasis or any other skin disease on the scalp (excluding medicated shampoos, emollients and hair conditioners) within 14 days prior to randomisation
•6. Topical treatment for other skin disorders with very potent WHO group IV corticosteroids within 14 days prior to randomisation.
•7. Planned initiation of, or changes in dose of concomitant medication that could affect scalp psoriasis (e.g., beta blockers, antimalarial drugs, lithium) during the study
•8. Current diagnosis of guttate, pustular, exfoliative or erythrodermic psoriasis.
•9. Patients with any of the following conditions present on the scalp area: viral lesions, fungal and bacterial skin infections, parasitic infections and atrophic skin
•10. Known or suspected severe renal insufficiency or severe hepatic disorders.
•11. Patients with history/ signs/ symptoms suggestive of an abnormality of calcium homeostasis associated with clinically significant hypercalcaemia.
•12. Known or suspected hypersensitivity to component(s) of the Investigational Products.
•13. Current participation in any other interventional clinical trial.
•14. Patients who have received treatment with any non-marketed drug substance (i.e., an agent which has not yet been made available for clinical use following registration) within 28 days prior to randomisation, or longer if the class of the substance requires a longer washout as defined above (e.g., biological treatments).
•15. Previously enrolled / randomised in this trial
•16. Patients known or suspected of not being able to comply with specifically a year-long trial design (e.g., due to alcoholism, drug dependency, psychotic state or general inability to make long term commitments).
•17. Females who are pregnant, or of child-bearing potential and wishing to become pregnant during the study, or are breast feeding.
•18. Females of child-bearing potential with positive pregnancy test at visit 1. (All females of child-bearing potential must have a pregnancy test at visit 1. Trial subjects should be using an adequate method of contraception.)

研究者

发起方

EO Pharma A/S

相似试验

进行中（未招募）

不适用

ong-term treatment of Scalp Psoriasis with Calciptriol plus Betamethasone dipropionate gel.A phase III safety study of a new gel containing calcipotriol 50mcg/g plus betamethasone 0.5 mg/g (as dipropionate) used once daily, as needed, in scalp psoriasis.Psoriasis of the scalpExtent: Minimum 10% of the total scalp areaDisease severity: Graded as moderate, severe, or very severe according to the investigator's global assessment of disease severityClinical signs of psoriasis vulgaris on trunk and/or limbs, or earlier diagnosed with psoriasis vulgaris on trunk and/or limbsMedDRA version: 7.0Level: LLTClassification code 10037115

EUCTR2004-002861-19-GBEO Pharmaceutical Products Ltd. A/S (LEO Pharma A/S)800

进行中（未招募）

不适用

EUCTR2004-002861-19-DEEO Pharma A/S800

已完成

3 期

Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Gel for up to a Year in Scalp PsoriasisPsoriasis of Scalp

NCT00216879LEO Pharma800

进行中（未招募）

1 期

Calcipotriol Plus Hydrocortisone in Psoriasis Vulgaris on the Face and on the Intertriginous Areas. A phase 3 study comparing an ointment containing calcipotriol 25 mcg/g plus hydrocortisone 10 mg/g (LEO 80190 ointment) with calcipotriol 25 mcg/g in the ointment vehicle, hydrocortisone 10 mg/g in the ointment vehicle and the ointment vehicle alone, all applied once daily in the treatment of psoriasis vulgaris on the face and on the intertriginous areas, followed by a 52-week safety study in patients with psoriasis vulgaris on the face and on the intertriginous areas.Psoriasis vulgaris on the face and on the intertriginous areas The face is defined as: forehead including hairline, cheeks, nose, chin and ears (excluding the auditory meatus). In case of baldness or partial baldness, the forehead should be estimated considering standard or previous hairline. The intertriginous areas are defined as: 1) the axillae, 2) the genito-femoral and inguinal folds, 3) the inframammary folds, 4) the intergluteal folds and 5) the scrotum.MedDRA version: 9.1 Level: LLT Classification code 10050576 Term: Psoriasis vulgaris

EUCTR2007-004782-18-GBEO Pharmaceuticals Products Ltd. A/S (LEO Pharma A/S)1,225

进行中（未招募）

不适用

Calcipotriol Plus Hydrocortisone in Psoriasis Vulgarison the Face and on the Intertriginous Areas. A phase 3 study comparing an ointment containing calcipotriol 25 mcg/g plus hydrocortisone 10 mg/g (LEO 80190 ointment) with calcipotriol 25 mcg/g in the ointment vehicle, hydrocortisone 10 mg/g in the ointment vehicle and the ointment vehicle alone, all applied once daily in the treatment of psoriasis vulgaris on the face and on the intertriginous areas, followed by a 52-week safety study in patients with psoriasis vulgaris on the face and on the intertriginous areas.Psoriasis vulgaris on the face and on the intertriginous areasThe face is defined as: forehead including hairline, cheeks, nose, chin and ears (excluding the auditory meatus). In case of baldness or partial baldness, the forehead should be estimated considering standard or previous hairline.The intertriginous areas are defined as: 1) the axillae, 2) the genito-femoral and inguinal folds, 3) the inframammary folds, 4) the intergluteal folds and 5) the scrotum.MedDRA version: 9.1Level: LLTClassification code 10050576Term: Psoriasis vulgaris

EUCTR2007-004782-18-SIEO Pharmaceutical Products Ltd. A/S (LEO Pharma A/S)1,225